Latest news about Brooks Laboratories
Brooks Laboratories
65.00
-2.05(-3.06%)
Company Performance:
View Company Insights1D-3.06%
1M+16.11%
6M-34.74%
1Y-56.33%
5Y-34.31%
More news about Brooks Laboratories
02Apr 26
Brooks Laboratories Clarifies Share Price Movement to BSE Under Regulation 30
Brooks Laboratories Limited clarified to BSE on April 2, 2026, regarding share price movement inquiry, confirming disclosure of all material information under SEBI Listing Regulations. The company stated no unpublished price sensitive information exists and attributed price changes to market forces, with management having no connection to price movements. Brooks Laboratories reaffirmed its commitment to regulatory compliance under listing obligations.
06Mar 26
Brooks Laboratories Updates on Scheme of Arrangement Progress Involving Brooks Steriscience Limited
Brooks Laboratories Limited has updated stakeholders on the progress of a composite scheme of arrangement involving its joint venture Brooks Steriscience Limited. The scheme has received no-objection letters from NSE and BSE, valid for six months. BSL's board will conduct a further review before filing the NCLT application, with completion planned within the approved timeframe.
30Jan 26
Brooks Laboratories Limited Receives ITAT Orders Dismissing Appeals for Assessment Years 2012-13, 2014-15 and 2016-17
Brooks Laboratories Limited disclosed that the Income Tax Appellate Tribunal (ITAT) Chandigarh Bench dismissed the company's appeals for Assessment Years 2012-13, 2014-15 and 2016-17. The appeals were filed against orders from the Commissioner of Income Tax (Appeals) and National Faceless Appeal Centre, where the company had received partial relief. Despite the dismissal, Brooks Laboratories stated there is no material impact on its financials, operations, or other business activities.
29Jan 26
Brooks Laboratories Limited Board Meeting Scheduled for February 6, 2026 to Consider Q3FY26 Unaudited Financial Results
Brooks Laboratories Limited has scheduled a board meeting for February 6, 2026, to consider and approve Q3FY26 unaudited financial results for the quarter and nine months ended December 31, 2025. The meeting will review both standalone and consolidated financial statements along with statutory auditors' Limited Review Report. Trading window restrictions remain in effect for directors and designated persons from January 1, 2026, until 48 hours after results declaration.
12Nov 25
Brooks Laboratories Receives Credit Rating Upgrade, Reflecting Improved Financial Outlook
CARE Ratings upgraded Brooks Laboratories Limited's (BLL) long-term bank facilities rating to 'CARE BB; Stable' from 'CARE BB-; Stable', while reaffirming its short-term rating at 'CARE A4'. The upgrade is based on expected financial performance improvements and benefits from a merger involving its associate company. BLL projects a total operating income of ~₹100 crore in FY26 with improved profit margins. The merger of BLL's associate, Brooks Steriscience Limited, into OneSource Speciality Pharma Limited is expected to enhance BLL's liquidity and financial risk profile.
26Sept 25
Brooks Steriscience Approves Multi-Entity Merger Scheme to Consolidate Sterile Injectable Operations
Brooks Steriscience Limited, a subsidiary of Brooks Laboratories, has approved a significant corporate restructuring plan involving a composite scheme of arrangement and amalgamation of five pharmaceutical entities. The merger aims to consolidate sterile injectable manufacturing operations under OneSource Specialty Pharma Limited. The scheme involves Steriscience Specialties Private Limited, Brooks Steriscience Limited, Steriscience Pte Limited, Strides Pharma Services Private Limited, and OneSource Specialty Pharma Limited. Share exchange ratios have been set, with post-merger promoter shareholding in OneSource expected to increase to 36.17%. The consolidation is designed to strengthen CDMO capabilities, create operational synergies, and enhance shareholder value. The scheme requires approvals from various regulatory authorities.
13Aug 25
Brooks Laboratories Reports Robust Q1 FY26 Results with 265.06 Lakh Net Profit
Brooks Laboratories Limited announced impressive Q1 FY26 results, posting a net profit of Rs. 265.06 lakhs compared to a loss in the previous year. Revenue surged 42.3% to Rs. 2,551.19 lakhs. Consolidated performance was even stronger with a net profit of Rs. 958.48 lakhs, boosted by its joint venture Brooks Steriscience Limited. The company's Basic EPS improved to Rs. 0.90 from negative Rs. 0.08 year-over-year.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Dr Reddys Laboratories
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,787.00
(-0.16%)
6,565.00
(+0.49%)
4,370.00
(+1.21%)
1,373.20
(-0.44%)
1,076.00
(-0.21%)
1,261.90
(-0.95%)
2,260.00
(+0.45%)
2,375.00
(+3.31%)
1,435.00
(+0.41%)
1,394.00
(+0.82%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
